Hematologic disorder
MONDO:0005570A disease involving the hematopoietic system.
Also known as: blood disease, blood disorder, disease of hematopoietic system, disease of the blood and blood-forming organs, disease or disorder of haematopoietic system, disease or disorder of hematopoietic system, disorder of haematopoietic system, disorder of hematopoietic system
8132 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1537 trials in this tab.
-
Engineered immune cells take aim at Hard-to-Treat leukemias
⭐️ CURE ⭐️ CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase: PHASE1, PHASE2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Aug 07, 2026 00:00 UTC
-
Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
⭐️ CURE ⭐️ CompletedThis trial is for adults with relapsed or refractory acute myeloid leukemia (AML) who have no standard curative options. Researchers are testing whether giving the drug gemtuzumab ozogamicin followed by an infusion of donor white blood cells can stimulate the immune system to att…
Phase: PHASE1, PHASE2 • Sponsor: Brown University • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
⭐️ CURE ⭐️ CompletedThis phase 2 trial tests a two-step approach to stem cell transplantation for people with blood cancers. The method separates the infusion of donor lymphocytes from stem cells, aiming to better control the dose and reduce the risk of graft-versus-host disease, a serious complicat…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Personalized leukemia vaccine aims to outsmart relapse
⭐️ CURE ⭐️ CompletedThis study tests a personalized vaccine made from a patient's own leukemia cells fused with immune cells, combined with a drug that blocks PD-1, to help the immune system recognize and destroy any remaining leukemia cells after chemotherapy. The goal is to prevent the cancer from…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 16, 2026 00:00 UTC
-
Can a short drug course end malaria relapses for good?
⭐️ CURE ⭐️ CompletedThis study tested how well the drug primaquine prevents the return of P. vivax malaria in 160 adults. Participants had uncomplicated malaria and normal G6PD levels. The goal was to see if a short treatment could stop relapses, aiming for a complete cure.
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New malaria vaccine shows promise in early human trial
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 18, 2026 02:00 UTC
-
Experimental malaria vaccine aims to block parasite growth
⭐️ VACCINE ⭐️ CompletedThis trial tests an experimental malaria vaccine called RH5.2-VLP, given with an adjuvant (Matrix-M) to boost the immune response. Healthy adults aged 18–45 receive three doses, and some volunteers are later exposed to malaria parasites in a controlled setting to see if the vacci…
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
New malaria vaccines show promise in protecting indonesian soldiers
⭐️ VACCINE ⭐️ CompletedThis study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Could a stem cell drug tame rare immune disease?
Disease control CompletedThis early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infe…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can Mountain-Like workouts help fatty liver? small trial aims to find out
Disease control CompletedThis study tests whether aerobic exercise in simulated altitude (normobaric hypoxia) can improve body composition and metabolism in people with MASLD, a type of fatty liver disease. Twenty sedentary adults with MASLD will walk on a treadmill for 8 weeks, either in mild altitude o…
Phase: NA • Sponsor: University of Trieste • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Immune cells supercharged to fight cancer: early trial shows promise
Disease control CompletedThis early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a pill keep blood cancer at bay after a stem cell transplant?
Disease control CompletedThis phase III trial is testing whether taking oral azacitidine as a maintenance therapy after an allogeneic stem cell transplant can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Participants are randomly assigned to receive…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
Disease control CompletedThis trial is testing an investigational drug called PF-06741086, given as a once-weekly injection under the skin, to see if it can reduce the number of bleeding episodes in people with severe hemophilia A or moderately severe to severe hemophilia B. The study includes both peopl…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a modified enzyme starve Hard-to-Treat blood cancers?
Disease control CompletedThis phase 1 trial is testing an investigational drug called AEB1102 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to standard treatments. AEB1102 is a modified human enzyme that breaks down arginine, an amin…
Phase: PHASE1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis study tested a new combination of drugs for people with Hodgkin lymphoma that either returned after treatment or didn't respond. The goal was to find the safest dose of a targeted drug (brentuximab vedotin) when added to standard chemotherapy. 45 adults took part, and the st…
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug duo outsmart resistant T-Cell lymphoma?
Disease control CompletedThis phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…
Phase: PHASE2 • Sponsor: John Reneau • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control CompletedThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Leukemia drug holiday: study tests if patients can pause nilotinib
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While th…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a common nerve pain drug restore brain chemistry in bipolar cannabis users?
Disease control CompletedThis study tests whether gabapentin, an FDA-approved medication, can help restore the balance of key brain chemicals (GABA and glutamate) in people with bipolar disorder who also use cannabis. Participants are randomly assigned to receive either gabapentin or a placebo for 17 day…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
Disease control CompletedThis trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…
Phase: PHASE1, PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Multi-Drug combo outsmart resistant lymphoma?
Disease control CompletedThis phase I trial is testing a combination of drugs—avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy—in people with diffuse large B-cell lymphoma or mantle cell lymphoma that has returned or not responded to treatment. The goal is to find the safest dose and see how …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Leukemia drug holiday: can patients stop nilotinib and stay Cancer-Free?
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who had very low levels of cancer cells could safely stop taking the drug nilotinib (Tasigna). Participants had already been treated with imatinib (Gleevec) and then nilotinib for at least 3 years. The main g…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail shows promise for rare bone marrow cancer
Disease control CompletedThis early-stage trial tests a combination of two drugs, venetoclax and azacitidine, in people with a serious type of myelodysplastic syndromes (MDS) who have not had treatment before. The goal is to find the safest dose and see how well the drugs work together to control the dis…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Gene therapy offers hope for hemophilia b patients
Disease control CompletedThis study tests a gene therapy (PF-06838435) for people with severe hemophilia B, a bleeding disorder. The therapy uses a harmless virus to deliver a working gene for clotting factor IX. Researchers are following 21 participants long-term to see if it is safe and reduces bleedin…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug offer hope for blood cancers when chemo fails?
Disease control CompletedThis trial is testing an experimental drug called BST-236 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not improved after initial treatment. Participants receive BST-236 as a one-hour intravenous infusion for six …
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
Disease control CompletedThis phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…
Phase: PHASE3 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can At-Home malaria pills work as well as supervised care?
Disease control CompletedThis trial compares two ways of taking the standard malaria treatment for Plasmodium vivax: one group receives chloroquine and primaquine under direct medical supervision, while the other takes the same medication at home with phone check-ins. The goal is to see if unsupervised t…
Phase: NA • Sponsor: Jimma University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Immune booster after CAR-T shows promise in early lymphoma trial
Disease control CompletedThis early-phase study tested an experimental drug called NT-I7 (efineptakin alfa) in 17 people with relapsed or refractory large B-cell lymphoma who had already received CAR-T cell therapy. The goal was to see if giving NT-I7 after CAR-T is safe and tolerable, and to look for ea…
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a drug revive blood cell production in children with aplastic anemia?
Disease control CompletedThis phase II trial is investigating whether eltrombopag, a drug that stimulates platelet production, can help children with severe aplastic anemia when combined with standard immunosuppressive therapy. The study will enroll children with newly diagnosed, relapsed, or refractory …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Lab-Grown stem cells supercharge blood recovery after transplant?
Disease control CompletedThis trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can engineered immune cells outsmart transplant-related cancer?
Disease control CompletedThis early-phase trial tests a new type of immunotherapy for people who develop a rare blood cancer called post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. The treatment uses the patient's own immune cells (T-cells) that are engineered to resist …
Phase: EARLY_PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThis study tested a new oral medication called iptacopan in 34 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal was to see if the drug could improve blood counts and kidney function w…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Chemotherapy-Free combo aims to boost remission in younger AML patients
Disease control CompletedThis phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a shorter TB regimen transform child care?
Disease control CompletedThis study looks at how a shorter tuberculosis (TB) treatment regimen works for children and adolescents with non-severe TB in Zambia. It involves children, caregivers, health workers, and policymakers to understand how well the regimen is accepted, followed, and feasible in real…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control CompletedThis study tests a combination of an immunotherapy drug (pembrolizumab) and low-dose radiation for people with non-Hodgkin lymphoma that has come back or not responded to prior treatments. Six participants will receive the drug plus radiation to one or more tumor sites. The goal …
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug DZD8586 enters phase 2 trial
Disease control CompletedThis phase 2 trial tests an experimental drug called DZD8586 in 59 adults with diffuse large B-cell lymphoma that has come back or not responded to previous treatment. The study aims to see if the drug can shrink tumors and to understand its side effects and how the body processe…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill tame myelofibrosis?
Disease control CompletedThis trial is testing an experimental oral drug called PXS-5505 (amsulostat) in people with myelofibrosis, a type of bone marrow cancer. The study focuses on patients who are not eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable, and t…
Phase: PHASE1, PHASE2 • Sponsor: Syntara • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Triple-Drug combo tame an aggressive lymphoma without harsh chemo?
Disease control CompletedThis phase 2 trial is testing whether a combination of three drugs—sintilimab, pegaspargase, and anlotinib—can effectively treat stage IV extranodal NK/T-cell lymphoma in patients who are not healthy enough for high-intensity chemotherapy. The study enrolls adults with newly diag…
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Three-Drug cocktail boost Radiation's power against a rare lymphoma?
Disease control CompletedThis trial is testing whether combining three drugs—camrelizumab, apatinib, and pegaspargase—with radiation therapy can improve outcomes for people with early-stage natural killer/T-cell lymphoma, a rare type of cancer. The study includes about 61 patients with stage IE or IIE di…
Phase: NA • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Shorter chemo shows promise for HIV patients with lymphoma
Disease control CompletedThis study tested a shorter course of a chemotherapy combination called EPOCH-R in 68 people with HIV and a type of lymphoma. The goal was to see if reducing the amount of chemotherapy could still control the cancer while causing less damage to the immune system. Participants rec…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
Disease control CompletedThis study follows adolescents and young adults (ages 12–21) with sickle cell disease who take hydroxyurea, a medication that helps prevent pain crises and other complications. The researchers are testing whether a mobile app called HU-Go can help these patients build a consisten…
Phase: NA • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a phone app keep teens on track with sickle cell treatment?
Disease control CompletedThis pilot trial tests whether a smartphone app called MED-Go can help adolescents and young adults with sickle cell disease take their daily hydroxyurea more consistently. Participants aged 12 to 21 will use the app for 12 weeks, and researchers will measure how often they log t…
Phase: NA • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a gentler iron pill break the anemia cycle in IBD?
Disease control CompletedThis trial tests whether ferric maltol, an oral iron supplement, can safely raise hemoglobin levels in adults with inflammatory bowel disease (IBD) who have iron deficiency anemia and have not responded to or cannot tolerate standard ferrous iron pills. Participants take either f…
Phase: PHASE3 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Leukemia drug holiday: study finds many can stop imatinib without relapse
Disease control CompletedThis study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a targeted drug boost stem cell transplant success in lymphoma?
Disease control CompletedThis trial tests whether adding the targeted drug venetoclax to standard BEAM chemotherapy before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory Non-Hodgkin lymphoma. Venetoclax works by blocking a protein that helps cancer cells su…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart drug missile tame Hard-to-Treat leukemia?
Disease control CompletedThis trial is investigating whether a targeted drug called CMC-544 (inotuzumab ozogamicin), given alone or later combined with rituximab, can control acute lymphoblastic leukemia (ALL) that has returned or not responded to standard treatment. The study enrolls adults and older ch…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a targeted drug boost standard chemo for an aggressive lymphoma?
Disease control CompletedThis phase 2 trial is investigating whether adding the targeted drug copanlisib to the standard R-CHOP chemoimmunotherapy regimen can help people with previously untreated diffuse large B-cell lymphoma (DLBCL) live longer without their cancer progressing. The study enrolls adults…
Phase: PHASE2 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a cancer drug's real-world performance match clinical trial results?
Disease control CompletedThis study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…
Sponsor: Sanofi • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted antibody boost chemotherapy against a rare leukemia?
Disease control CompletedThis study tests whether adding a targeted drug called brentuximab vedotin to standard chemotherapy can help people with adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive blood cancer. The combination, known as BV-CHEP, aims to improve response rates by targeting a mar…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A drug that may speed platelet recovery after stem cell transplants in kids
Disease control CompletedThis study explores whether romiplostim, a drug that stimulates platelet production, can safely and effectively help platelet recovery in children with thalassemia who receive a half-matched stem cell transplant. Researchers will track how quickly platelet levels rise, how many p…
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use p…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A drug that boosts platelets may speed recovery after stem cell transplants in kids with thalassemia
Disease control CompletedThis observational study tests whether hetrombopag, a platelet-boosting drug, can safely speed platelet recovery in children with thalassemia who receive a half-matched (haploidentical) stem cell transplant. Thirty children aged 2 to 17 will be followed for 28 days after transpla…
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Triple threat: could three malaria drugs together beat resistance?
Disease control CompletedThis trial tests whether giving children with uncomplicated malaria a triple combination of artemisinin-based drugs works better than the standard two-drug treatment. The goal is to see if using three drugs together can delay the malaria parasite from becoming resistant. Children…
Phase: PHASE2, PHASE3 • Sponsor: Muhimbili University of Health and Allied Sciences • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Which vein is safer for chemotherapy ports? a trial aims to settle the debate
Disease control CompletedThis trial compares two common methods for placing a totally implantable vascular access device (TIVAD), a port used for chemotherapy and other treatments in cancer patients. Researchers are randomly assigning patients to have the port inserted via either the internal jugular vei…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a diet and exercise program help childhood leukemia survivors live healthier?
Disease control CompletedThis trial tests whether a personalized diet and exercise program, delivered by phone and online, can help adult survivors of childhood leukemia who are overweight or obese lose weight. Participants are randomly assigned to either the active coaching program or a self-directed ap…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A smartphone app may help young cancer survivors get fitter — a trial puts it to the test
Disease control CompletedThis phase 3 trial tests whether a web-based physical activity program, including a wearable tracker and interactive app, can improve fitness and long-term health in children and adolescents who have completed cancer treatment. Participants are randomly assigned to receive either…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Tailored hormone dosing may spare preemies from blood transfusions
Disease control CompletedThis phase 2 trial tests whether personalized dosing of epoetin alfa—a lab-made hormone that boosts red blood cell production—can reduce or eliminate the need for blood transfusions in very low birth weight premature infants with neonatal anemia. Researchers will study how the dr…
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug gilteritinib takes on standard therapy in FLT3 leukemia trial
Disease control CompletedThis Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …
Phase: PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill tame a common blood cancer in the real world?
Disease control CompletedThis study follows about 269 people with chronic lymphocytic leukemia (CLL) who are starting venetoclax, a targeted pill. Researchers will track how well the drug shrinks or controls the cancer over the first year, and how long it takes before patients need another treatment. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
Disease control CompletedThis phase 2 trial tests a personalized approach for people with newly diagnosed, advanced classical Hodgkin lymphoma. After two cycles of standard chemotherapy, patients are grouped based on a PET scan. Those with a moderate response receive the immunotherapy drug sintilimab plu…
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a 5-Day drug course make surgery safer for liver patients with low platelets?
Disease control CompletedThis study tests whether a 5-day course of avatricopal can safely raise platelet counts in people with chronic liver disease who have low platelets and need surgery. The goal is to see if more patients reach a platelet count of at least 50×10⁹/L on the day of their procedure, whi…
Sponsor: Beijing Ditan Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood transfusion thresholds tested to save elderly surgical patients
Disease control CompletedThis study tests whether giving blood transfusions more liberally (when hemoglobin drops to 9 g/dL) versus more restrictively (when it drops to 7.5 g/dL) reduces death and serious complications like heart attack, stroke, or kidney injury in patients aged 70 and older undergoing n…
Phase: PHASE3 • Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Iron fix: new study tests best way to boost energy in women with hidden deficiency
Disease control CompletedThis study looked at 1331 women aged 18-45 who had low iron stores but normal hemoglobin (no anemia). They were split into three groups: one got daily oral iron pills for 3 months, another got three IV iron infusions over 3 months, and a third got no treatment. The goal was to se…
Phase: NA • Sponsor: Akram Medical Complex • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Leukemia drug cocktail aims to boost remission in High-Risk patients
Disease control CompletedThis study tests whether adding the targeted drug venetoclax to standard chemotherapy helps more adults with acute myeloid leukemia (AML) achieve remission. It enrolls people aged 18 to 65 with intermediate- or high-risk AML who have not yet been treated. The main goal is to see …
Phase: PHASE2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a peer coach help young people take control of their chronic illness?
Disease control CompletedThis study tests whether a peer coaching program delivered by phone and text can help adolescents and young adults (ages 16–22) with chronic conditions like sickle cell disease, diabetes, or cystic fibrosis improve their self-management skills. Participants are paired with a trai…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could heart failure drugs boost oral Iron's power against anemia?
Disease control CompletedThis study looks at whether heart failure patients with iron deficiency anemia respond better to oral iron supplements when they are also taking a type of heart medication called SGLT2 inhibitors. Participants take oral iron for three to four months, then pause treatment while do…
Phase: PHASE3 • Sponsor: Universidade do Porto • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Real-World check: does bosutinib control CML safely?
Disease control CompletedThis study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the …
Sponsor: Pfizer • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One-shot gene therapy aims to free hemophilia patients from constant infusions
Disease control CompletedThis trial tests a gene therapy called valoctocogene roxaparvovec for people with severe hemophilia A who have developed inhibitors (antibodies that block standard treatment). The therapy uses a harmless virus to deliver a working copy of the gene for clotting factor VIII, so the…
Phase: PHASE1, PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
Disease control CompletedThis study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will mon…
Phase: NA • Sponsor: LucasBio • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a JAK inhibitor improve stem cell transplant success in myelofibrosis?
Disease control CompletedThis phase 2 trial tests whether giving ruxolitinib (Jakafi) before, during, and after a stem cell transplant can improve outcomes for people with myelofibrosis. The study includes patients with intermediate-2 or high-risk disease, or intermediate-1 with additional risk factors. …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for sickle cell: Half-Matched transplants show promise
Disease control CompletedThis phase 2 trial tested a half-matched (haploidentical) bone marrow transplant in 95 children and adults with severe sickle cell disease. The goal was to see if this approach could help patients live without major complications for two years. Participants received a reduced-int…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Deep gum cleaning may boost quality of life for hemophilia patients
Disease control CompletedThis study tests whether non-surgical gum treatment (deep cleaning) can improve oral health and quality of life in adults with hemophilia A or B. Researchers compare changes in gum health and daily comfort (using a questionnaire) between hemophilia patients and healthy individual…
Phase: NA • Sponsor: Karadeniz Technical University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Drug cocktail aims to tame advanced leukemia
Disease control CompletedThis phase 2 trial is testing whether combining two drugs, ponatinib and 5-azacitidine, can improve survival in people with advanced chronic myeloid leukemia (CML). The study includes adults whose CML has progressed to an accelerated phase or a more aggressive blast crisis. Parti…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized dasatinib dosing aims to tame leukemia with fewer side effects
Disease control CompletedThis study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Diabetes drug could help eradicate hidden leukemia cells
Disease control CompletedThis phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo aims to outsmart aggressive leukemia
Disease control CompletedThis trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age gro…
Phase: PHASE1, PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental drug aims to tame rare mast cell disease
Disease control CompletedThis phase 2 trial tests whether the drug RAD001 (everolimus) can help control systemic mastocytosis, a rare condition where too many mast cells build up in organs like the bone marrow. Ten adults with the disease take a daily pill for 30 days. Researchers measure success by chan…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a lower dose of an old antibiotic tame Drug-Resistant TB?
Disease control CompletedThis study tests whether a low daily dose of the antibiotic linezolid, added to a personalized combination of other drugs, is safe and tolerable for people with multidrug-resistant tuberculosis (MDR-TB). Participants take either linezolid or a placebo for 16 weeks, alongside thei…
Phase: PHASE1, PHASE2 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalizing leukemia drug doses could boost treatment success
Disease control CompletedThis trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental drug aims to boost immunity in rare WHIM syndrome
Disease control CompletedThis phase 3 trial tests whether mavorixafor can raise neutrophil levels in people with WHIM syndrome, a rare genetic condition that weakens the immune system. Participants receive either mavorixafor or a placebo to see if the drug helps maintain infection-fighting white blood ce…
Phase: PHASE3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lymphoma in early human test
Disease control CompletedThis early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One infusion could beat daily pills for Post-Birth anemia
Disease control CompletedThis study tests whether a single intravenous (IV) dose of iron works better than daily oral iron pills to treat moderate anemia in new mothers. About 4,800 women who have moderate anemia 6 to 48 hours after delivery will receive either a one-time IV iron infusion plus folic acid…
Phase: PHASE3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cuts chemotherapy side effect by over 60% in breast cancer patients
Disease control CompletedThis study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
IV iron may beat pills for anemia in late pregnancy
Disease control CompletedThis study tests whether a single intravenous dose of ferumoxytol raises hemoglobin more effectively than daily oral ferrous sulfate in pregnant women with iron deficiency anemia. Participants are between 24 and 34 weeks pregnant with a single baby. The trial measures hemoglobin …
Phase: PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
Disease control CompletedThis phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…
Phase: PHASE2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for frail AML patients: stronger chemo regimens tested
Disease control CompletedThis study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a month of iron before knee or hip surgery cut transfusion risk?
Disease control CompletedThis trial investigates whether anemic patients scheduled for hip or knee replacement surgery benefit from taking an iron supplement (Sideremil Vita) for 30 days before the operation, compared to taking it for only 15 days. The goal is to see if the longer treatment reduces the n…
Phase: NA • Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat blood cancers
Disease control CompletedThis study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
Disease control CompletedThis Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Rare disease drug shows promise in reducing infections
Disease control CompletedThis study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection…
Phase: PHASE2, PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control CompletedThis study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…
Phase: PHASE1, PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
Disease control CompletedThis large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug strategy may reduce blood transfusions after organ transplants
Disease control CompletedThis study looked at whether giving romiplostim, a drug that boosts platelet production, could reduce the need for platelet transfusions in patients with low platelet counts after heart or lung transplantation or use of heart/lung support devices. Researchers compared a group of …
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
Disease control CompletedThis study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase: PHASE1, PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered stem cells aim to speed recovery in blood cancer patients
Disease control CompletedThis trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Triple-Drug cocktail aims to boost remission in acute myeloid leukemia
Disease control CompletedThis phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell …
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to deepen remission in multiple myeloma
Disease control CompletedThis phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…
Phase: PHASE2 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental pill targets Hard-to-Treat blood cancers
Disease control CompletedThis study tested a daily pill called E7820 in 12 adults with relapsed or treatment-resistant acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. All participants had specific mutations in splicing factor genes. The goal was to see if the drug c…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug cocktail may cut transfusions for kids with thalassemia
Disease control CompletedThis study tested whether giving children with transfusion-dependent thalassemia a combination of hydroxyurea and thalidomide works better than either drug alone. Ninety children aged 3-18 were split into three groups: one getting both drugs, one getting only hydroxyurea, and one…
Phase: PHASE4 • Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple supplement ease sickle cell symptoms?
Disease control CompletedThis study tested a nutraceutical supplement called NUV001 in 168 adults with sickle cell disease. Participants took either an immediate-release or gastro-resistant version of NUV001, or a placebo, daily for 90 days. The main goal was to check safety and tolerability, with early …
Phase: NA • Sponsor: LGD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Herbal ointment shows promise for eczema relief
Disease control CompletedThis completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…
Phase: NA • Sponsor: VinUniversity • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows early promise for recurrent lymphoma
Disease control CompletedThis early-phase trial tested two drugs, lenalidomide and idelalisib, in 8 people with follicular lymphoma that had returned after previous treatment. Lenalidomide helps the immune system fight cancer, while idelalisib blocks enzymes that cancer cells need to grow. The main goal …
Phase: PHASE1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Iron shot beats pills for new Moms' anemia?
Disease control CompletedThis study tested whether an iron injection works better than iron pills for treating anemia in 200 new mothers within 10 days of giving birth. Participants had mild to moderate anemia and were randomly assigned to receive either a single injection of ferric carboxymaltose or ora…
Phase: PHASE2, PHASE3 • Sponsor: ESI-PGIMSR, Basaidarapur • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New sickle cell drug candidate enters first human tests
Disease control CompletedThis early-stage trial tested a new drug called PF-07209326 in 52 people, first in healthy volunteers and then in patients with sickle cell disease. The main goal was to check safety and how the body processes the drug. Researchers also looked for any early signs that the drug mi…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Treadmill training boosts fitness in anemic women
Disease control CompletedThis study tested whether adding a structured treadmill walking program to standard iron therapy improves exercise tolerance and quality of life in young women with mild-to-moderate iron deficiency anemia. Sixty women aged 18-28 were split into two groups: one received iron suppl…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may shield cancer Patients' hearts from chemo damage
Disease control CompletedThis study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…
Phase: PHASE1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for elderly lymphoma patients: a gentler treatment that preserves independence
Disease control CompletedThis phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody shot shows promise against malaria in early trial
Disease control CompletedThis early-stage trial tested a lab-made antibody called MAM01 in 63 healthy adults who had never had malaria. The goal was to see if it is safe and can prevent malaria infection when people are deliberately exposed to the parasite. The study is complete, but results are not yet …
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug doses tested for rare blood cancer
Disease control CompletedThis phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and r…
Phase: PHASE2 • Sponsor: InnoCare Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody combo aims to tackle Hard-to-Treat multiple myeloma
Disease control CompletedThis trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New oxygen test could cut unnecessary blood transfusions after heart surgery
Disease control CompletedThis study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase: PHASE2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise for rare blood cancer in Late-Stage trial
Disease control CompletedThis phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randoml…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a pill keep mantle cell lymphoma away? new study tests ibrutinib maintenance
Disease control CompletedThis study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free …
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New toothpaste fights gum disease in 12-Week trial
Disease control CompletedThis study tested whether a stannous fluoride toothpaste can reduce gum inflammation, bleeding, and plaque better than a standard fluoride toothpaste. Over 12 weeks, 133 adults brushed with one of the two toothpastes and had their gums checked at several visits. The goal was to s…
Phase: NA • Sponsor: Church & Dwight Company, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for tough lymphoma: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells target tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immune cell infusion shows promise against post-transplant blood cancer relapse
Disease control CompletedThis early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New lymphoma treatment aims to boost cure rates and cut radiation risks
Disease control CompletedThis study tested a combination of brentuximab vedotin and AVD chemotherapy in 118 adults with newly diagnosed, early-stage Hodgkin lymphoma that is considered unfavorable. The goal was to see if this treatment could cure more patients while reducing long-term side effects, espec…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New chemo cocktail shows promise in myeloma stem cell transplants
Disease control CompletedThis phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Iron pills for babies: daily or weekly? new study has answers
Disease control CompletedThis study tested whether giving iron supplements daily or weekly works better to prevent anemia in healthy Thai infants aged 6 to 12 months. A total of 287 babies were randomly assigned to receive iron daily or weekly for 3 months, then all switched to weekly for another 3 month…
Phase: NA • Sponsor: Mahidol University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control CompletedThis completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for PNH patients in china: eculizumab shows promise
Disease control CompletedThis study tested eculizumab in 25 adults with PNH in China who had not previously taken complement inhibitors. Participants received infusions over 62 weeks. The main goal was to see if the drug reduced LDH levels, a marker of disease activity. Results showed a decrease in LDH, …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo tackles tough lymphoma
Disease control CompletedThis study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to s…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…
Phase: PHASE3 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a biomarker predict who responds to a new AML combo?
Disease control CompletedThis phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Gut bacteria drug shows promise against blood disorder
Disease control CompletedThis early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug may offer longer-lasting bleed control for rare platelet disorder
Disease control CompletedThis lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second-line drug help CML patients stay cancer-free without daily pills?
Disease control CompletedThis study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy for hemophilia b shows promise in Long-Term study
Disease control CompletedThis study follows 9 adults with severe or moderately severe hemophilia B who received a one-time gene therapy (AAV5-hFIX) to help their bodies produce clotting factor IX. Researchers are checking if the treatment remains safe and effective for up to 10 years after the initial do…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug may help liver transplant patients avoid bleeding complications
Disease control CompletedThis study looked at whether the drug avatrombopag can safely and effectively raise platelet counts in people who develop dangerously low platelets after a liver transplant. Researchers compared 67 patients who received the drug with 67 similar patients who got standard care. The…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy shows promise for older hodgkin lymphoma patients
Disease control CompletedThis phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targe…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental 'In-Situ' vaccine aims to train immune system against three cancers
Disease control CompletedThis early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental combo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Real-world data: luspatercept may cut transfusion needs in MDS patients
Disease control CompletedThis study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with erythropoiesis-stimulating agents. They were given luspatercept, and researchers tracked how many became free from red blood cell transfusions and whe…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New blood thinner may simplify stroke prevention after heart surgery
Disease control CompletedThis study tested whether a newer blood thinner, rivaroxaban (Xarelto), is as safe and effective as the older drug warfarin for preventing strokes in people who develop atrial fibrillation after heart surgery. About 100 adults who had open-heart surgery and then experienced a new…
Phase: PHASE3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for AML patients: drug combo targets leukemia cells
Disease control CompletedThis study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Old drug, new hope for rare skin cancer?
Disease control CompletedThis study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with rare bleeding disease: study tests rVWF therapy
Disease control CompletedThis study tested a medicine called vonicog alfa (rVWF), sometimes given with another drug (ADVATE), to control bleeding in 47 children under 18 with severe von Willebrand disease. The treatment was given for 12-18 months, and doctors checked how well it stopped bleeding and if i…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rare gut disease? small study tests biologic drug
Disease control CompletedThis study tested a drug called ustekinumab in 8 people with a rare, severe form of Behçet's syndrome affecting the gut, along with a blood disorder called myelodysplastic syndrome. The goal was to see if the drug could control gut symptoms and reduce disease activity over 24 wee…
Phase: PHASE2 • Sponsor: Liu Tian • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for untreated lymphoma patients
Disease control CompletedThis study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThis phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Gene-Editing breakthrough offers hope for blood disorder patients
Disease control CompletedThis early-stage study tested a new gene-edited stem cell transplant in 2 children with severe β-thalassemia, a serious blood disorder requiring lifelong transfusions. The treatment aims to help the body produce healthy red blood cells and reduce or stop the need for transfusions…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Second stem cell transplant shows promise for returning myeloma
Disease control CompletedThis study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for older AML patients: triple drug combo aims to control disease and prevent relapse
Disease control CompletedThis study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …
Phase: PHASE1, PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New transplant strategy shows promise for blood cancer relapse
Disease control CompletedThis study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedThis study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug safety check for tough blood cancer
Disease control CompletedThis study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a simple drink help blood cancer patients recover from stem cell transplants?
Disease control CompletedThis study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Rabbit antibodies show promise for rare bone marrow disease
Disease control CompletedThis phase 2 trial tested a combination of rabbit antithymocyte globulin (Thymoglobuline) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this rabbit-based immune-suppressing tre…
Phase: PHASE2 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise in early trial for rare blood disorder
Disease control CompletedThis early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also look…
Phase: PHASE1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill could reduce Blood-Letting for rare blood cancer patients
Disease control CompletedThis phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the drug pair could shrink tumors. The …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Real-World check: newer PNH drug holds up in routine care
Disease control CompletedThis study followed 120 adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from the older drug eculizumab to the newer ravulizumab. Researchers measured changes in a blood marker called LDH to see if the new drug controlled red blood cell breakdown just as well or…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for myeloma relapse after transplant
Disease control CompletedThis study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…
Phase: PHASE2 • Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill shows promise for rare blood disorder
Disease control CompletedThis study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Pill may replace shots for blood cancer patients, study finds
Disease control CompletedThis study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…
Phase: PHASE2 • Sponsor: University of Florence • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a drug shorten dialysis for kids with a rare kidney disease?
Disease control CompletedThis study tested whether the drug eculizumab (Soliris) can help children with a severe kidney condition called STEC-HUS recover faster. The trial gave 100 children either eculizumab or a placebo over several weeks. The main goal was to see if the drug reduces the number of days …
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug may help MDS patients need fewer blood transfusions
Disease control CompletedThis study tested a drug called luspatercept in 30 adults from China and Japan who have a bone marrow disorder (MDS) and need regular red blood cell transfusions. The goal was to see if the drug could help them go without transfusions for at least 8 weeks. The drug works by helpi…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough blood cancers? early trial tests LYT-200
Disease control CompletedThis early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not…
Phase: PHASE1 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radiation technique aims to safely prepare blood cancer patients for transplant
Disease control CompletedThis study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug ABC008 tested for rare blood cancer
Disease control CompletedThis study tested a new drug called ABC008 in 21 adults with T-cell large granular lymphocytic leukemia (T-LGLL), a rare blood cancer. The drug was given as a shot under the skin. The main goal was to check for side effects and see how the drug affects blood counts and other lab …
Phase: PHASE1, PHASE2 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody infusion shows promise for immune deficiency patients
Disease control CompletedThis study tested a new intravenous immunoglobulin (IVIg) treatment called Kedrion IVIg 10% in 47 people with primary immunodeficiency, a condition where the immune system cannot make enough antibodies. The goal was to see if regular infusions of this antibody therapy could preve…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
High-Dose chemo and stem cell transplant shows promise for HIV lymphoma patients
Disease control CompletedThis early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment p…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug shows promise
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could help adults with low platelet disorder
Disease control CompletedThis Phase 3 trial tested an oral drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants who had not responded well to prior treatments received eith…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and help control the dis…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Tiny trial hopes drug can ease liver damage in rare triple condition
Disease control CompletedThis completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very s…
Phase: PHASE2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for young leukemia patients: combination chemo shows promise
Disease control CompletedThis study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase: PHASE2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New stem cell transplant approach shows promise for blood disorders
Disease control CompletedThis pilot study tested a stem cell transplant from closely matched unrelated donors for 8 patients with severe sickle cell disease or thalassemia major. The donated stem cells were specially processed to remove certain immune cells to reduce the risk of rejection and graft-versu…
Phase: NA • Sponsor: Timothy Olson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for aggressive myeloma
Disease control CompletedThis study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…
Phase: PHASE1, PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can metformin or hydroxyurea cut transfusions for thalassemia patients?
Disease control CompletedThis completed Phase 4 trial tested two drugs—hydroxyurea and metformin—in 96 people with transfusion-dependent beta-thalassemia. Participants took one of the two drugs for a year. Researchers measured changes in fetal hemoglobin levels and how often blood transfusions were neede…
Phase: PHASE4 • Sponsor: Bahria University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedThis study tested a new medicine called HBM9161, given as a weekly shot under the skin, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising the risk of bleeding. The trial included 36 people who had not responded…
Phase: PHASE2, PHASE3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New targeted pill shows promise for rare blood cancer
Disease control CompletedThis Phase 2 study tested avapritinib, a daily tablet that targets a specific genetic mutation, in 107 people with advanced systemic mastocytosis (a rare blood cancer). The main goal was to see how many patients had their tumors shrink or symptoms improve. Results suggest the dru…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo aims to tame hairy cell leukemia with fewer side effects
Disease control CompletedThis study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…
Phase: PHASE2 • Sponsor: Scripps Health • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New COPD treatment cuts hospital returns in severe cases
Disease control CompletedThis study tested whether a drug called mepolizumab, given after a severe COPD flare-up that required hospital care, could prevent future hospital stays or death. It involved 238 adults with eosinophilic COPD (a type with high levels of certain white blood cells). Participants re…
Phase: PHASE2, PHASE3 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for rare bone marrow failure
Disease control CompletedThis study tested whether adding eltrombopag to standard immunosuppressive therapy improves early recovery in patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. 202 participants received either standard treatment (horse a…
Phase: PHASE3 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested the safety of a drug called duvelisib when given with either romidepsin or bortezomib for adults with T-cell lymphoma that returned or didn't respond to prior treatment. The study involved 114 participants and aimed to find the highest safe dose. Thi…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThis study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a cancer drug fix an irregular heartbeat?
Disease control CompletedThis study looked at whether Vidaza, a drug used for acute leukemia, could also help treat atrial fibrillation (an irregular heartbeat). The idea was that Vidaza might reverse certain DNA changes that lower the activity of a gene important for heart function. Only one person took…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to deepen remissions in myeloma patients
Disease control CompletedThis phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent co…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a daily pill boost blood counts in aplastic anemia?
Disease control CompletedThis study tested the drug eltrombopag in 34 people with moderate aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Eltrombopag is a pill that mimics a natural protein to stimulate blood cell production. Researchers measured whether it safely imp…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo tackles relapsed lymphoma in small trial
Disease control CompletedThis phase 2 study tested a combination of two drugs, bendamustine and rituximab, in 27 people with relapsed or progressive marginal zone B-cell lymphoma. The goal was to see how well the treatment shrank or controlled the cancer. Participants had already tried at least one prior…
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a cancer drug stop myeloma before it starts?
Disease control CompletedThis phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested an oral chemotherapy drug, azacitidine, against standard treatments in 86 patients with a rare type of T-cell lymphoma that had returned or not responded to prior therapy. The main goal was to see if the oral drug could delay cancer progression. The stud…
Phase: PHASE3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Iron showdown: which anemia drug works best for kidney patients?
Disease control CompletedThis completed study looked at 128 adults with chronic kidney disease (not on dialysis) who also had iron-deficiency anemia. Researchers compared two intravenous iron treatments—ferric carboxymaltose and iron sucrose—to see which raises hemoglobin and iron levels better and with …
Phase: NA • Sponsor: Sindh Institute of Urology and Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink lymphoma with less radiation
Disease control CompletedThis study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination…
Phase: PHASE2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New asthma drug shows promise in real-world greek study
Disease control CompletedThis study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearabl…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…
Phase: PHASE1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a platelet booster keep chemo on track for lymphoma patients?
Disease control CompletedThis phase 2 study tested whether the drug romiplostim can prevent severe low platelet counts caused by chemotherapy in people with lymphoma. Eleven adult patients received weekly injections of romiplostim during their 21-day chemo cycles. The goal was to see if it could reduce t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising combo tackles aggressive lymphoma in large trial
Disease control CompletedThis Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heart surgery breathing study aims to cut lung failure risk
Disease control CompletedThis study tested two ways of managing breathing during heart bypass surgery to see which better prevents lung complications. Over 1,500 adults having planned heart surgery were randomly assigned to either no breathing support or gentle, low-volume breaths while on the heart-lung…
Phase: NA • Sponsor: CMC Ambroise Paré • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo aims to supercharge cancer immunotherapy
Disease control CompletedThis early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a vaccine and immune drug keep myeloma away after transplant?
Disease control CompletedThis study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Clot-Busting catheter shows promise in leg vein blockages
Disease control CompletedThis study looked at how well the JETi device works in real-world settings to remove blood clots from deep leg veins (venous thrombosis). The device uses suction and tiny water jets to break up and remove clots. In 121 patients, the device successfully cleared at least 75% of the…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Smart baby gym could predict motor delays before they start
Diagnosis CompletedThis study is testing a new way to detect motor delays in infants using a special play mat with sensors and a smart toy. Researchers will watch how babies move and interact with the toy, then use AI to spot early signs of disability. The goal is to create an easy, objective tool …
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New scan could spot lymphoma without PET
Diagnosis CompletedThis early study tested a new radioactive tracer called 99mTc-1-thio-D-glucose in 16 adults with Hodgkin or non-Hodgkin lymphoma. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it went in the body. The goal was to check safety and whether the …
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New fingerstick test for blood thinner monitoring put to the test
Diagnosis CompletedThis study tested how well a small, portable device (LumiraDx) measures blood clotting (INR) compared to standard lab tests. Researchers collected blood from 420 adults, some taking warfarin and some not, using both a fingerstick and a vein draw. The goal was to see if the device…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Fingerprick test for blood thinners put to the test
Diagnosis CompletedThis study tested whether a fingerstick blood test (LumiraDx INR test) gives accurate results for people taking the blood thinner phenprocoumon. Researchers compared fingerstick results to standard lab tests in 102 adults. The goal is to see if this quick test can reliably monito…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging method could speed up diagnosis of blood clotting disorders
Diagnosis CompletedThis study tested a new diagnostic tool that uses imaging flow cytometry to examine platelets in blood samples. Researchers compared it to standard lab tests in 31 patients suspected of having platelet disorders or heparin-induced thrombocytopenia. The goal was to see if the new …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could speed up Life-Saving treatment for HUS patients
Diagnosis CompletedThis study tested a new blood test designed to quickly determine whether the complement system is involved in a serious kidney condition called thrombotic microangiopathy (TMA). The test measures complement deposits on cells in a lab sample. Researchers compared test results to h…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New PET tracer aims to spot hidden cancers without biopsy
Diagnosis CompletedThis completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New ultrasound could spot heart trouble before It's too late for chemo patients
Diagnosis CompletedThis study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
Protein fingerprints may spot hidden transplant rejection
Diagnosis CompletedThis study tested whether analyzing proteins from kidney biopsy and urine samples can improve the diagnosis of microvascular inflammation, a key sign of antibody-mediated rejection in kidney transplant recipients. Researchers used mass spectrometry to find protein signatures in 1…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
New PET tracer shows promise for spotting myeloma bone lesions
Diagnosis CompletedThis study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
Minutes, not days: new rapid test could speed up thyroid cancer detection
Diagnosis CompletedThis study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…
Sponsor: Soroka University Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Blood thinners after vein laser: which works best to stop dangerous clots?
Prevention CompletedThis trial tests whether a short 5-day course of the blood thinners rivaroxaban (Xarelto) or apixaban (Eliquis) can prevent blood clots that sometimes form after laser treatment for varicose veins. Adults with symptomatic vein reflux undergoing laser ablation of the great sapheno…
Phase: PHASE4 • Sponsor: Heart, Artery, and Vein Center of Fresno • Aim: Prevention
Last updated Jul 18, 2026 00:00 UTC
-
New shot may shield transplant patients from deadly immune attack
Prevention CompletedThis study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if aba…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New antibiotic may replace standard infection prevention in blood cancer patients
Prevention CompletedThis study tested whether fosfomycin, an older antibiotic, works as well as ciprofloxacin for preventing serious infections in people with blood cancers like leukemia or those receiving a stem cell transplant. 177 adults from 11 Spanish hospitals took part. The main goal was to s…
Phase: PHASE3 • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New shot could shield against malaria for months
Prevention CompletedThis study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored…
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Text reminders help get young kids vaccinated on time
Prevention CompletedThis study tested whether sending text message reminders to parents could increase routine vaccination rates in children aged 0-2 years. Over 1,000 families in Brooklyn, New York, whose children were behind on vaccines received texts when shots were due or coming due. The goal wa…
Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
New 'Star Homes' aim to slash childhood disease in tanzania
Prevention CompletedThis study tested whether specially built houses (Star Homes) could reduce malaria, respiratory infections, and diarrhea in children under 13 in rural Tanzania. Over 1,100 children lived either in a Star Home or a traditional mud house. The Star Homes have screened windows, solar…
Phase: NA • Sponsor: University of Oxford • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could targeted drug dosing stamp out malaria in thai hotspots?
Prevention CompletedThis study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail aims to stop transplant rejection
Prevention CompletedThis phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Can your own fat help heal scars?
Symptom relief CompletedThis study tests whether a single injection of nanofat—made from a person's own fat—can improve the appearance of atrophic scars caused by burns or trauma. Each participant has two similar scars: one gets the nanofat injection plus silicone gel, and the other gets only silicone g…
Phase: NA • Sponsor: Benha University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can music and mindfulness ease the toll of stem cell transplants?
Symptom relief CompletedThis study tests an electronic program that combines mindfulness and music therapy for people undergoing stem cell transplants for blood cancers. The goal is to see if it improves quality of life and reduces symptoms like pain. About 60 adults will participate, and the program in…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Could gratitude exercises aid blood cancer recovery?
Symptom relief CompletedThis trial tests whether a phone-based positive psychology program can improve mood, quality of life, and daily functioning in adults who have just undergone a stem cell transplant for blood cancer. Participants receive weekly calls and complete exercises focused on gratitude, pe…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Could carbon monoxide be a medicine? new trial for sickle cell
Symptom relief CompletedThis study tests a new liquid drug called HBI-002, which contains carbon monoxide, in 9 people with sickle cell disease aged 14 to 55. Participants take the drug daily for 14 days to see if it is safe and helps with symptoms. The goal is to find a better way to manage this painfu…
Phase: PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New program aims to ease lymphoma Survivors' fear of recurrence
Symptom relief CompletedThis study tests a program called UPLYFT designed to help lymphoma survivors who have finished treatment cope with the fear that their cancer might return. The program provides information and tools to improve quality of life and reduce worry. Researchers will first gather feedba…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a computer program tame sickle cell pain crises?
Symptom relief CompletedThis trial tests a computer-based tool called PAINRelieveIt for adults with sickle cell disease, a condition that causes intense pain episodes. The tool has three parts: one helps patients report their pain, another educates them about pain management, and a third helps doctors c…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Heart-Smart chemo: new infusion method aims to protect AML patients
Symptom relief CompletedThis early-stage study looked at whether giving two standard chemotherapy drugs (cytarabine and daunorubicin) in a different way could be safer for the heart in adults newly diagnosed with acute myeloid leukemia (AML). Researchers used heart MRI scans to monitor for damage. The g…
Phase: PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
A cup of lavender tea a day may keep PMS blues away — science puts it to the test
Symptom relief CompletedThis trial tests whether drinking lavender herbal tea twice daily for nine days around each menstrual cycle can reduce the emotional and physical symptoms of premenstrual syndrome (PMS), such as anxiety, depression, stress, and pain. Sixty women with PMS will be randomly assigned…
Phase: NA • Sponsor: Sakarya University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could End-of-Life care for blood cancer patients be done at home?
Symptom relief CompletedThis study tests whether a hospital-at-home care model can help people with advanced blood cancers receive end-of-life care at home instead of in the hospital. Participants use remote monitoring and home-based supportive care, with researchers tracking how many enroll and complet…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could kids have upper limb surgery fully awake? new trial tests the idea
Symptom relief CompletedThis trial tests whether a local anesthetic injection (ropivacaine) can keep children aged 6 to 12 awake and comfortable during upper limb surgery, avoiding general anesthesia. Children watch cartoons on a tablet for distraction while the anesthetic is given. The study aims to se…
Phase: PHASE4 • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could an amino acid shorten sickle cell pain crises?
Symptom relief CompletedThis phase 3 trial tests whether intravenous arginine, an amino acid, can shorten painful episodes in children with sickle cell disease. Participants aged 3 to 21 receive either arginine or a placebo alongside standard pain treatment. The study measures how quickly the crisis res…
Phase: PHASE3 • Sponsor: Claudia R. Morris • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Talking therapy shows promise for MG patients with depression in tiny pilot study
Symptom relief CompletedThis study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…
Phase: NA • Sponsor: Ming-Hsing Chang • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New supplement shows promise for sickle cell sufferers in early trial
Symptom relief CompletedThis study tested a daily dietary supplement called NUV001 in 12 adults with sickle cell disease (SS type) over 120 days. The main goals were to see if it is safe and tolerable, and to measure its effects on blood health and quality of life. Researchers tracked side effects, hosp…
Phase: NA • Sponsor: LGD • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could an ancient herb ease Chemo's worst side effects?
Symptom relief CompletedThis study tests whether PG2, a compound from the astragalus root, can reduce fatigue and low white blood cell counts caused by chemotherapy in women with stage II or III breast cancer. Participants receive either PG2 or a placebo alongside their standard chemotherapy. The goal i…
Phase: PHASE2 • Sponsor: PhytoHealth Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New program helps caregivers of stem cell patients cope better
Symptom relief CompletedThis study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could chemo at home become a reality for myeloma patients?
Symptom relief CompletedThis study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…
Sponsor: Thomas Lund • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New sponge stops bleeding faster after wisdom tooth extraction
Symptom relief CompletedThis study tested a new dental sponge called Colibricare (Coli-sorb®) in 124 patients having their wisdom teeth removed. The sponge was compared to a standard gauze and a commercial sponge. Researchers measured how quickly bleeding stopped, pain levels, swelling, and wound healin…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Talking away the tiredness: CBT tackles Post-Transplant fatigue
Symptom relief CompletedThis study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Hot water rinse during sinus surgery may stop bleeding faster
Symptom relief CompletedThis study tested whether rinsing the sinuses with hot saline (50°C) during surgery for chronic sinusitis reduces bleeding and improves the surgeon's view. 59 adults were split into three groups: hot saline, room-temperature saline, or no rinse. The goal was to see if the hot rin…
Phase: NA • Sponsor: Military Institute of Aviation Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Ancient remedy takes on chemo nerve damage
Symptom relief CompletedThis study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…
Phase: NA • Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Exercise program shows promise for hemophilia patients
Symptom relief CompletedThis study tested whether a 6-month adapted physical activity program could improve functional capacity in people with hemophilia. Fourteen participants did exercises twice a week to improve joint mobility, strength, and balance. The main goal was to see if their walking distance…
Phase: NA • Sponsor: Istituto Ortopedico Rizzoli • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Special PE program shows promise for building muscle in teens with intellectual disability
Symptom relief CompletedThis study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…
Phase: NA • Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a sedative stop Post-Surgery agitation in children?
Symptom relief CompletedThis completed study tested whether giving children the drug dexmedetomidine during tonsillectomy surgery could reduce pain and agitation afterward. 85 children aged 2-10 took part. Researchers measured pain and anxiety levels after the operation to see if the drug helped compare…
Sponsor: Burak Omur • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a Live-Streaming brain health program boost memory in older adults?
Symptom relief CompletedThis study tested a 12-week online program called Brain Health Together for older adults with mild cognitive decline. Participants joined live-streaming exercise and education classes, plus individual coaching, all from home. The goal was to see if the program could improve think…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Talking therapy shows promise for trauma in people with learning disabilities
Symptom relief CompletedThis study tested whether an adapted form of Narrative Exposure Therapy (NET) is acceptable and helpful for adults with mild learning disabilities who have experienced trauma. Thirteen participants completed the therapy, which involved talking through their life events in a struc…
Phase: NA • Sponsor: University of Nottingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists decode myeloma DNA to personalize future treatments
Knowledge-focused CompletedThis study will analyze the genetic makeup of tumors from 100 people with relapsed multiple myeloma. Researchers will use advanced DNA and RNA sequencing to find genetic changes and understand how the cancer works. The goal is to gather information that could guide more personali…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can a global patient registry unlock the secrets of a rare muscle disease?
Knowledge-focused CompletedThis study is building an international registry of people with GNE myopathy, an ultra-rare muscle disease that causes progressive weakness and often leads to wheelchair use. Participants will complete online questionnaires about their symptoms, medical history, quality of life, …
Sponsor: Newcastle University • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Sickle cell patients checked for hidden lung danger
Knowledge-focused CompletedThis study measured how common pulmonary hypertension (high blood pressure in the lungs) is in adults with sickle cell anemia. Nearly 1,000 participants had heart ultrasounds and blood tests, then were contacted by phone for up to 3 years to track their health. The goal was to un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can tracking severe asthma over time unlock better treatments?
Knowledge-focused CompletedThis research program aims to deepen understanding of severe asthma by closely studying its clinical and biological features over time. Researchers will follow more than a thousand people with asthma, aged 6 and older, measuring lung function and tracking how often severe asthma …
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
HIV cancer study reveals who gets sick and why
Knowledge-focused CompletedThis study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affe…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
NIH launches major study to unlock secrets of rare inflammatory diseases
Knowledge-focused CompletedThis study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Local cereals fortified with vitamins could boost teen health in rural ethiopia
Knowledge-focused CompletedThis study looked at whether adding folic acid and vitamin B12 to locally made cereals can improve the nutrition, thinking skills, and mood of teenage girls in rural Ethiopia. About 472 girls aged 13-19 took part. The goal was to see if small-scale food fortification can help pre…
Phase: NA • Sponsor: University Ghent • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
Knowledge-focused CompletedThis large observational study across multiple African sites tracks pregnant women who use antimalarial drugs, especially in the first trimester. The goal is to assess whether these medications are linked to miscarriage, stillbirth, or major birth defects. By following thousands …
Sponsor: Liverpool School of Tropical Medicine • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Body position may predict fluid needs during keyhole hysterectomy
Knowledge-focused CompletedThis study looks at how a simple monitor called the Pleth Variability Index (PVI) changes during laparoscopic-assisted vaginal hysterectomy. Researchers will track PVI at six key moments when the patient's body position changes, such as tilting the head down or raising the legs. …
Sponsor: Wonkwang University Hospital • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Healthy men needed to track Drug's path out of the body
Knowledge-focused CompletedThis early-stage study looks at how a drug called Flonoltinib maleate (being developed for a bone marrow condition) is processed and removed from the body. Six healthy adult men will take a single dose, and researchers will measure the drug and its breakdown products in blood, ur…
Phase: PHASE1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists hunt for allergy genes in massive screening study
Knowledge-focused CompletedThis study screened up to 1,000 people with severe allergic conditions—like anaphylaxis, eczema, and asthma—along with their relatives to find genetic causes. Researchers collected blood samples and medical history to link specific gene mutations to these diseases. No treatment w…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New blood test could help patients who Don't respond to platelet transfusions
Knowledge-focused CompletedThis study looked at 68 people with low platelet counts who had become resistant to platelet transfusions due to HLA antibodies. Researchers tested a new lab method (C1q binding) on stored blood samples to see if it could better predict whether a transfusion would work compared t…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A simple blood test trend may flag ICU patients at risk
Knowledge-focused CompletedThis observational study looks at whether a fast drop in hemoglobin during the first 24 hours in the ICU can predict a longer stay (8 days or more) or death in the hospital. Researchers will review medical records of about 128 critically ill adults, comparing their hemoglobin lev…
Sponsor: Hospital H+ Queretaro • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can Ultra-Processed foods make you eat more? a study investigates
Knowledge-focused CompletedThis study aims to understand how ultra-processed foods affect energy metabolism compared to unprocessed foods. Healthy adults aged 18-60 will stay at a research center for four weeks, eating different diets each week. Researchers will measure how much they eat, their metabolic r…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can Co-Designed support help parents embrace sickle cell care?
Knowledge-focused CompletedThis study aims to understand why some parents of children with sickle cell disorder (SCD) may not engage with health services during the first year after diagnosis, and to co-design strategies with parents and health professionals to improve support accessibility. The research i…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists probe blood changes during sickle cell pain crises
Knowledge-focused CompletedThis study looked at what happens in the blood of people with sickle cell disease during painful attacks. Researchers compared blood samples taken during a pain crisis to samples taken when participants were feeling well. The goal was to learn more about the role of inflammation …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New document helps young adults voice End-of-Life wishes
Knowledge-focused CompletedThis study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could a platelet-boosting drug shorten recovery after stem cell transplants?
Knowledge-focused CompletedThis study looks back at medical records of people who had an allogeneic stem cell transplant to see whether romiplostim helped their platelets recover faster. Platelets are blood cells that help clotting, and low counts are common after transplant. The researchers will compare p…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Small study aims to unlock secrets of rare lung disease
Knowledge-focused CompletedThis completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms.…
Phase: PHASE1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New study aims to unravel why hemophilia pain disrupts daily life
Knowledge-focused CompletedThis observational study will look at 138 adults with hemophilia and joint damage to understand how central pain mechanisms and psychological factors like anxiety affect pain interference in daily activities. Researchers will measure pain intensity, sleep quality, and pain self-e…
Sponsor: Investigación en Hemofilia y Fisioterapia • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can your genes predict blood thinner effectiveness?
Knowledge-focused CompletedThis trial investigates whether genetic variations in the CES1 gene influence how the body responds to the blood thinners clopidogrel and aspirin. Healthy Amish adults will take clopidogrel for a week, then a single dose of aspirin, with blood tests measuring platelet function be…
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Blood clot score may predict organ damage in septic shock
Knowledge-focused CompletedSeptic shock is a life-threatening condition where infection leads to dangerously low blood pressure. Many patients also develop disseminated intravascular coagulation (DIC), a disorder that causes abnormal blood clotting throughout the body. This study will follow 60 adults in t…
Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Can Real-World data unlock clues to a deadly Post-Transplant complication?
Knowledge-focused CompletedThis study looks back at medical records of children and adults who developed a serious blood-clotting condition called thrombotic microangiopathy (TMA) within a year after a stem cell transplant. Researchers aim to understand survival rates and causes of death in these patients,…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Your DNA could determine which heart drug works best
Knowledge-focused CompletedThis trial investigates whether a common genetic variation in the CES1 gene affects how the body processes two antiplatelet drugs, clopidogrel and ticagrelor. Healthy volunteers of Amish descent will take each drug for eight days in a crossover design, and researchers will measur…
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can a closer look at bone complications in multiple myeloma improve rehabilitation?
Knowledge-focused CompletedMultiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Rare childhood bone lymphoma: can past cases guide future care?
Knowledge-focused CompletedThis study looks back at 21 children and teens diagnosed with a rare type of lymphoma that starts in the bone. Researchers are collecting medical records to describe how the disease presents, how it was treated, and how well patients did over time. The goal is to learn more about…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can Eye-Tracking reveal hidden brain risks in babies with sickle cell disease?
Knowledge-focused CompletedSickle cell disease can affect brain development even in very young children. This study uses eye-tracking—a simple, non-invasive method—to measure attention and processing speed in infants aged 6 to 24 months. The goal is to identify those at highest risk for cognitive challenge…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Fine-Tuning MRI scanners to sharpen the picture of the brain
Knowledge-focused CompletedThis study uses a research-dedicated 3T MRI scanner to develop and optimize imaging protocols in healthy adults. Researchers aim to reduce image distortions, improve contrast and resolution, and create new sequences for functional MRI. The work will help enable future studies in …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?
Knowledge-focused CompletedThis study compares three devices that measure how well blood clots — ClotPro, ROTEM, and TEG — in patients undergoing liver surgery, neurosurgery, or cesarean section. The goal is to see how closely the results from these devices agree with each other. The findings may help doct…
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Wearable patch and phone app could spot dangerous fevers before they spike in cancer therapy
Knowledge-focused CompletedThis study tests two devices — a wearable temperature patch and a smartphone app that measures vital signs from a facial scan — in adults with blood cancers receiving CAR-T or bispecific T-cell engager therapy. The goal is to see if these tools can detect fevers and other signs o…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Exosomes: the decoy receptors that may sabotage lymphoma treatment
Knowledge-focused CompletedThis study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By …
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
Knowledge-focused CompletedThis study looks at how mepolizumab (Nucala), a treatment for severe eosinophilic asthma, impacts emotions and mental well-being in patients and their partners. Researchers will track changes in feelings like anxiety, depression, and stress using questionnaires and interviews. Th…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Tracking Real-World safety of treatments for a rare bleeding disorder
Knowledge-focused CompletedThis study follows people with severe von Willebrand disease (VWD) to see how well different treatments work and how safe they are in everyday use. Researchers are tracking side effects and how the body responds to therapy given on demand, during surgery, or as regular prevention…
Sponsor: American Thrombosis and Hemostasis Network • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Real-World data may reveal best Second-Line therapy for multiple myeloma
Knowledge-focused CompletedThis study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Scientists hunt for genetic roots of rare childhood blood disorder
Knowledge-focused CompletedThis study investigates the genetic causes of pediatric Evans syndrome, a rare autoimmune condition where the immune system attacks blood cells. Researchers analyze blood samples from affected children and their families to find known or new mutations. The goal is to better under…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Malaria's next threat: drug-resistant parasites spread even after treatment
Knowledge-focused CompletedThis study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…
Phase: PHASE4 • Sponsor: Infectious Diseases Research Collaboration, Uganda • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
Knowledge-focused CompletedThis study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…
Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists hunt for hidden genetic causes of rare bleeding disorder
Knowledge-focused CompletedThis study investigates inherited thrombocytopenias, rare conditions where low platelet counts cause bleeding problems. About half of patients have an unknown genetic cause. Researchers aim to identify new disease genes and build a lab-grown bone marrow model to test how well dru…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World data reveals how bosutinib fights leukemia outside clinical trials
Knowledge-focused CompletedThis study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
Knowledge-focused CompletedThis study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Researchers review CAR T-Cell results in kids with B-ALL
Knowledge-focused CompletedThis study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Are sickle cell patients becoming addicted to pain relief? new study investigates
Knowledge-focused CompletedThis completed observational study looked at how often young people with sickle cell disease (under 26) in France develop problematic use of painkillers and a gas mixture called EMONO. Researchers interviewed over 1,000 patients by phone to check for signs of addiction or depende…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who will get chronic ITP?
Knowledge-focused CompletedThis completed study looked at blood samples from 70 children and adults newly diagnosed with immune thrombocytopenic purpura (ITP), a condition that causes easy bruising and bleeding. Researchers wanted to see if certain immune and blood markers could predict whether the disease…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can scans and blood predict CAR T-Cell success?
Knowledge-focused CompletedThis pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New guide aims to help myeloma patients stick to their pill regimen
Knowledge-focused CompletedThis study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Transplant vs. standard care: which protects sickle cell Kids' brains better Long-Term?
Knowledge-focused CompletedThis study followed 67 children with sickle cell disease who had a high risk of stroke. Researchers compared those who received a bone marrow transplant to those who got standard care, checking brain scans and thinking skills 9-10 years later. The goal was to see which approach b…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered imaging could revolutionize anemia diagnosis
Knowledge-focused CompletedThis study tested a new way to analyze red blood cells in people with anemia using flow imaging and artificial intelligence. Instead of the usual method of spreading blood on a slide and staining it, the researchers used a machine that takes pictures of cells flowing in liquid. T…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could natural immune cells help fight leukemia drug resistance?
Knowledge-focused CompletedThis completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Japanese study tracks Esperoct's Real-World safety over two years
Knowledge-focused CompletedThis study watched 23 people with hemophilia A who were already using Esperoct as part of their normal care. Researchers tracked side effects and how well the medicine worked over about two years. The goal was to confirm the drug's safety and effectiveness in everyday use, not to…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New eDiary helps track sickle cell pain and fatigue
Knowledge-focused CompletedThis study tested an electronic diary for adults with sickle cell disease to track daily symptoms like pain, tiredness, and ability to do usual activities. About 98 participants used the diary for 6 months, and researchers compared those on disease-modifying treatment to those no…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Weighty issue: does obesity block iron supplements?
Knowledge-focused CompletedThis study examined the link between obesity and iron deficiency anemia in 165 nonpregnant Indonesian women aged 19-29. Participants took daily iron-folic acid supplements for 90 days. Researchers compared iron levels between overweight/obese and normal-weight women to see if wei…
Phase: NA • Sponsor: Griffith University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clot clues in sickle cell blood
Knowledge-focused CompletedThis study examined blood samples from 119 adults with sickle cell disease, sickle cell trait, or no condition to understand why some develop dangerous blood clots. Participants gave blood and had health check-ins over two years. The goal was to find biomarkers that could lead to…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Hidden deficiencies in black college athletes under the microscope
Knowledge-focused CompletedThis pilot study investigates how common low energy availability, iron deficiency, and low vitamin D levels are among Black collegiate athletes. Participants who are found to have low iron or vitamin D will receive daily supplements for 12 weeks. The goal is to better understand …
Phase: NA • Sponsor: Morehouse School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gene test spots hidden leukemia in kids
Knowledge-focused CompletedThis study looked at 148 children with T-cell acute lymphoblastic leukemia to see if a high-tech gene test could find tiny amounts of cancer left after treatment. Researchers used next-generation sequencing to check for specific gene changes in immune cells. They then compared th…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Scientists hunt for hidden genes behind common bleeding disorder
Knowledge-focused CompletedThis study examined the DNA of 254 people to find genetic changes that might explain why some individuals have mildly low levels of von Willebrand factor, a protein important for blood clotting. Researchers used whole-exome sequencing to look for variants in known and new genes. …
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Which drug works better for stem cell collection? study compares zarzio and granocyte
Knowledge-focused CompletedThis completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Instacart and nutrition calls may ease food insecurity for cancer survivors
Knowledge-focused CompletedThis study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Bone loss in hemophilia: new study measures the hidden risk
Knowledge-focused CompletedThis study looked at bone density in 448 men with hemophilia and healthy volunteers to see how common bone loss is. Participants had a bone density scan and some gave blood samples. The goal was to understand if hemophilia itself, not just lack of activity, leads to weaker bones.
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Hidden danger: why some patients can't shake COVID-19
Knowledge-focused CompletedThis study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…
Sponsor: Maddalena Giannella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Which drug combo works best for returning myeloma?
Knowledge-focused CompletedThis study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Study reveals vaccine response in Immune-Compromised patients
Knowledge-focused CompletedThis study looked at how people with autoimmune diseases like multiple sclerosis or blistering skin conditions respond to COVID-19 vaccines while on B-cell depleting therapies. Researchers measured antibody levels and T-cell activity over time to understand vaccine effectiveness …
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Scientists dig into DNA to unravel blood clot mysteries in rare disorder
Knowledge-focused CompletedThis study looks at people with a rare inherited condition called dysfibrinogenemia, which affects how blood clots form. Researchers collected blood samples from 70 patients to analyze clot structure and search for genetic variations that might explain why some patients bleed whi…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Scientists probe the root cause of a rare bone marrow disease
Knowledge-focused CompletedThis completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists track lifespan of transfused blood in sickle cell kids
Knowledge-focused CompletedThis study looked at how long donor red blood cells survive in children with sickle cell disease who get regular blood transfusions. Researchers labeled a small part of the transfused blood with a harmless marker and tracked it over time. The goal was to better understand why som…
Phase: PHASE1 • Sponsor: Marianne Yee • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Tiny camera may spot hidden bleeding in rare blood disorder
Knowledge-focused CompletedThis study looked at whether using a video capsule endoscopy (a small camera pill) along with standard scopes can better find the source of gut bleeding in people with von Willebrand disease. Researchers reviewed records of 50 patients who had gut bleeding between 2015 and 2017. …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Rare bleeding disorder study seeks to unlock antibody mystery
Knowledge-focused CompletedThis study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study reveals how well COVID vaccines protect myeloma patients
Knowledge-focused CompletedThis study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…
Sponsor: ASH Research Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
C-Section bleeding study: does tranexamic acid help clotting?
Knowledge-focused CompletedThis study examined how the drug tranexamic acid (TXA) affects blood clotting in women having planned C-sections. Researchers measured clot breakdown times in 34 participants to see if TXA could help prevent heavy bleeding after delivery. The goal was to better understand how TXA…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Large study checks safety of rituximab pfizer in lymphoma patients
Knowledge-focused CompletedThis study looked at medical records from over 2,700 people in Japan with a type of lymphoma (B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer. The goal was to see how often infections and other side effects happened, and to compare these results with those f…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Blood cell study may personalize asthma and sinusitis treatment
Knowledge-focused CompletedThis study looked at different types of immune cells (eosinophils) in the blood of people with asthma, chronic sinusitis with nasal polyps, or both, compared to healthy volunteers. The goal was to find patterns that could help doctors choose the best targeted therapy for each pat…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Lupus clue: can a heart drug reveal hidden disease markers?
Knowledge-focused CompletedThis small pilot study looked at whether clopidogrel, a drug that stops blood clots, could lower a substance called sCD40L in people with lupus. Lupus is an autoimmune disease where the body attacks itself. The study involved 18 adults with lupus and measured sCD40L levels in the…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Mold infection risk in kids with leukemia: a 14-year review
Knowledge-focused CompletedThis study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…
Sponsor: University of Southern Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could your diet trigger lupus? new study investigates
Knowledge-focused CompletedThis study measured phytoestrogens (plant-based compounds) in the blood and urine of 63 premenopausal women with active lupus, other autoimmune diseases, or no disease. Researchers also asked about diet and measured estradiol levels. The goal was to see if these dietary compounds…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New surgical clip tool tested in 161 patients
Knowledge-focused CompletedThis study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.
Sponsor: Teleflex • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New study aims to predict dangerous bleeding during weight-loss surgery
Knowledge-focused CompletedThis study looked back at the records of over 9,000 people who had weight-loss (bariatric) surgery. The goal was to find factors that might predict bleeding during or within 30 days after surgery. By identifying these risk factors, doctors hope to create a score that can help pre…
Sponsor: Assuta Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Magnesium levels linked to clotting risk in sepsis
Knowledge-focused CompletedThis study looked at 150 adults with sepsis in the ICU to see if low magnesium levels are connected to blood clotting problems. Researchers measured magnesium and clotting markers at admission and tracked outcomes like DIC and survival. The goal was to understand if magnesium cou…
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Ultrasound breakthrough: can it spot cancer in lymph nodes?
Knowledge-focused CompletedThis study tested a new ultrasound technique to see the smallest blood vessels in lymph nodes on the neck. Researchers wanted to know if this method could tell the difference between healthy and cancerous lymph nodes. Twenty adults with head and neck cancer, lymphoma, or healthy …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Anemia duration may predict ventilator days in ICU patients
Knowledge-focused CompletedThis study examined 236 adults in a surgical intensive care unit who needed a breathing machine for more than 4 days. Researchers wanted to see if the length of time a patient had anemia (low red blood cells) was linked to how long they stayed on the ventilator. The goal was to b…
Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Antibiotic side effects under the microscope in bone infection study
Knowledge-focused CompletedThis completed study followed 73 adults with bone or joint infections who needed antibiotics for at least 6 weeks. Researchers tracked how often side effects occurred, how severe they were, and whether they affected quality of life. The goal was to understand why some patients st…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists probe the hidden types of severe childhood asthma
Knowledge-focused CompletedThis completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Exercise may boost heart fitness in hodgkin survivors
Knowledge-focused CompletedThis study looked at whether exercise training can improve physical capacity and heart function in adults who survived Hodgkin lymphoma after chemotherapy and chest radiation. Forty survivors took part in fitness tests and heart monitoring. The goal was to see if exercise could r…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Which iron pill works best? small study tests natural vs. standard supplements
Knowledge-focused CompletedThis completed study looked at how well healthy pre-menopausal women with low iron stores absorb iron from two different supplements: Spatone (a natural iron-rich water) and ferrous sulphate (a standard iron pill). Fourteen women took three different doses (5, 10, and 15 mg) of e…
Phase: NA • Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple ultrasound spot hidden liver danger in immune disorder patients?
Knowledge-focused CompletedThis study looked at whether ultrasound and stiffness measurements of the liver and spleen can predict a serious condition called portal hypertension in people with common variable immunodeficiency (CVID). Researchers examined 250 CVID patients during routine visits, using non-in…
Sponsor: University Hospital Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New drug EP395 tested in humans for first time
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18-65. Participants received either EP395 or a placebo capsule, and researchers monitored side effects, vital signs, and hearing. The goal was to find a safe dose range …
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Sickle cell drug safety in pregnancy: small study completed
Knowledge-focused CompletedThis completed study monitored pregnancy and infant outcomes in 13 women with sickle cell disease who were treated with the drug crizanlizumab (Adakveo) during pregnancy or shortly before. The goal was to track rates of fetal loss and birth defects. Because it was a small observa…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Can a computer program help doctors decode clotting tests?
Knowledge-focused CompletedThis study tested whether a new software program helps doctors more accurately interpret ROTEM blood clotting tests. Twenty-six doctors and residents from the University of Utah took part. Researchers compared their answers before and after using the software to see if it improve…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Study compares quality of life for boys on different hemophilia drugs
Knowledge-focused CompletedThis completed observational study looked at boys aged 7-18 with moderate or severe hemophilia A in Canadian treatment centres. Researchers compared quality of life and caregiver burden between those receiving an intravenous factor replacement product and those on a subcutaneous …
Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can VR keep kids active and engaged after school? new study explores
Knowledge-focused CompletedThis study tested a virtual reality (VR) afterschool program for 32 children ages 9-17. The goal was to see if kids would use and enjoy the VR system, and to measure their physical activity. This was a pilot study to gather information, not to treat or cure any disease.
Phase: NA • Sponsor: University of Georgia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden signs in blood cancers to personalize treatment
Knowledge-focused CompletedThis study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Iron deficiency in cancer: a hidden problem exposed
Knowledge-focused CompletedThis study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Diet sheds light on iron deficiency in obesity
Knowledge-focused CompletedThis study looked at how weight loss from a calorie-restricted diet affects iron levels in people with obesity and iron deficiency. Researchers measured a protein called hepcidin, which controls iron in the body, along with iron levels before and after a 60-day diet. The goal was…
Phase: NA • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Malaria drug resistance confirmed in ethiopia: study raises alarm
Knowledge-focused CompletedThis study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specif…
Phase: NA • Sponsor: Didier Menard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC